Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00830739 · ClinicalTrials.gov registry record

A Multi-Modal Investigation of the Smoking Cessation Medication Varenicline: Dopaminergic Modulation of Reward Processing and Cognitive Control

A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
61
Enrollment target

NCT00830739: Completed study, sponsored by National Institute on Drug Abuse (NIDA).

NCT00830739 is a clinical trial that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00830739 has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
61 participants
Enrollment target

Study Summary

Background: * Chronic nicotine exposure through cigarette smoking affects the level of the brain chemical dopamine. Smokers who attempt to quit experience lower levels of dopamine, which increases anxiety and triggers nicotine cravings that make quitting more difficult. * Varenicline (Chantix) is a smoking cessation medication that is designed to reduce nicotine craving and withdrawal by slightly increasing levels of dopamine in the brain. Research has shown that varenicline is a safe, well-tolerated, and effective treatment for nicotine dependence, but researchers are interested in learning more about how it affects the brain and its function. Functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) will help researchers study the brain s response to nicotine and varenicline. Objectives: \- To explore how varenicline affects brain function and behavioral performance in current smokers and healthy volunteers. Eligibility: \- Individuals between 18 and 55 years of age who are either current smokers (10 or more cigarettes per day) or healthy nonsmoking volunteers. Design: * The study will involve nine testing and research visits over 5 to 6 weeks. The first visit will provide an initial assessment and training on the tasks that will be completed during the study. * Six testing visits will involve fMRI and EEG measurements of brain activity. Each visit will contain two 2-hour scanning sessions, and each session will involve thinking tests. During these visits, participants will receive varenicline and placebo tablets, and wear nicotine patches and placebo patches that do not contain nicotine. Participants will not be told which tablet or patch they are given. This is a crossover study so all participants eventually get nicotine and placebo, as well as varenicline and placebo. * Two other visits involve different thinking tasks. These visits will not require fMRI or EEG scans.

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2008-11-25
Est. Completion 2013-02-26

What the finished NCT00830739 record still lists

NCT00830739 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 61 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT00830739 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00830739 about?

NCT00830739 is a clinical study titled "A Multi-Modal Investigation of the Smoking Cessation Medication Varenicline: Dopaminergic Modulation of Reward Processing and Cognitive Control". Background: * Chronic nicotine exposure through cigarette smoking affects the level of the brain chemical dopamine. Smokers who attempt to quit experience lower levels of dopamine, which increases anxiety and triggers nicotine cravings that make quitting more difficult. * Varenicline (Chantix) is a...

What is the current status of trial NCT00830739?

This trial is currently completed. The enrollment target is 61 participants. The study started on 2008-11-25. Estimated completion is 2013-02-26.

Who is sponsoring clinical trial NCT00830739?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04115306 · 61 participants · Phase 1

    Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

  • NCT05070845 · 61 participants · Phase 2

    Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

  • NCT05187832 · 61 participants · Phase 1

    A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

  • NCT05269316 · 61 participants · Phase 1

    Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00830739, the US trial registry maintained by the National Library of Medicine. NCT00830739 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.